[{"orgOrder":0,"company":"SKNV","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2025","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"||Thymidylate synthase | RNA | DNA","graph1":"Dermatology","graph2":"Approved FDF","graph3":"SKNV","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"SKNV \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"SKNV \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"GSK \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ GSK"},{"orgOrder":0,"company":"Polichem S.A.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Polichem S.A.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Polichem S.A. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Polichem S.A. \/ Undisclosed"},{"orgOrder":0,"company":"Polichem S.A.","sponsor":"Almirall","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Polichem S.A.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Polichem S.A. \/ Almirall","highestDevelopmentStatusID":"10","companyTruncated":"Polichem S.A. \/ Almirall"},{"orgOrder":0,"company":"Tulane University","sponsor":"Mayne Pharma Do Brasil Ltda","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Tulane University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Tulane University \/ Mayne Pharma Do Brasil Ltda","highestDevelopmentStatusID":"6","companyTruncated":"Tulane University \/ Mayne Pharma Do Brasil Ltda"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Leo Pharma"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Leo Pharma"},{"orgOrder":0,"company":"Psoriasis Treatment Center of Central New Jersey","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Psoriasis Treatment Center of Central New Jersey","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Psoriasis Treatment Center of Central New Jersey \/ Eli Lilly","highestDevelopmentStatusID":"11","companyTruncated":"Psoriasis Treatment Center of Central New Jersey \/ Eli Lilly"},{"orgOrder":0,"company":"Wake Forest University","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Wake Forest University","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wake Forest University \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"Wake Forest University \/ Leo Pharma"},{"orgOrder":0,"company":"Tolmar","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Tolmar","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Tolmar \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Tolmar \/ Undisclosed"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ GSK"},{"orgOrder":0,"company":"Mayne Pharma Do Brasil Ltda","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"BRAZIL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase I","graph3":"Mayne Pharma Do Brasil Ltda","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Mayne Pharma Do Brasil Ltda \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Mayne Pharma Do Brasil Ltda \/ GSK"},{"orgOrder":0,"company":"Leon Kircik, M.D.","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Leon Kircik, M.D.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Leon Kircik, M.D. \/ GSK","highestDevelopmentStatusID":"11","companyTruncated":"Leon Kircik, M.D. \/ GSK"},{"orgOrder":0,"company":"Derm Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"Derm Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Derm Research \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Derm Research \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Lipidor AB","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cadila Pharmaceuticals \/ Lipidor AB","highestDevelopmentStatusID":"10","companyTruncated":"Cadila Pharmaceuticals \/ Lipidor AB"},{"orgOrder":0,"company":"Cadila Pharmaceuticals","sponsor":"Lipidor AB","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Cadila Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cadila Pharmaceuticals \/ Lipidor AB","highestDevelopmentStatusID":"10","companyTruncated":"Cadila Pharmaceuticals \/ Lipidor AB"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Hyphens Pharma","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Hyphens Pharma","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Hyphens Pharma"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Almirall"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Endo Pharm","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Endo Pharm","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Endo Pharm"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MC2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"MC2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MC2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"MC2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Tigermed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Tigermed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Undisclosed"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Bioskin","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Bioskin","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Bioskin"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Undisclosed"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0.080000000000000002,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Menarini"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Undisclosed"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Undisclosed"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Lipidor AB \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Quintiles Inc","highestDevelopmentStatusID":"15","companyTruncated":"Leo Pharma \/ Quintiles Inc"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase IV","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Foam","sponsorNew":"University of Alabama at Birmingham \/ Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"University of Alabama at Birmingham \/ Leo Pharma"},{"orgOrder":0,"company":"EPI Health","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"EPI Health \/ MC2 Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ MC2 Therapeutics"},{"orgOrder":0,"company":"EPI Health","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Approved FDF","graph3":"EPI Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"EPI Health \/ MC2 Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"EPI Health \/ MC2 Therapeutics"},{"orgOrder":0,"company":"Egymedicalpedia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Egymedicalpedia","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Egymedicalpedia \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Egymedicalpedia \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Calcipotriol","moa":"Vitamin D receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Leo Pharma \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Dovonex (TN)
Details :
Kefunova Cream (Fluorouracil/Calcipotriene), a new topical therapy developed in direct response to the needs of dermatology providers treating actinic keratosis & superficial basal cell carcinoma.
Details :
The agreement aims to commercialize Wynzora Cream, a combination of calcipotriene and betamethasone dipropionate, a corticosteroid, indicated for the topical treatment of plaque psoriasis, in Canada.
Details :
Enstilar is a combination of calcipotriene hydrate as a synthetic vitamin D3 analog and betamethasone dipropionate as a synthetic corticosteroid, indicated as topical treatment of plaque psoriasis.
Details :
MC2 gains commercialization rights for Wynzora, an approved product indicated for treating plaque psoriasis in patients 18 years and older, through a license agreement.
Details :
Calcipotriol is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Alopecia Areata.
Details :
The product is the combination of calcipotriene hydrate as a synthetic vitamin D3 analog and betamethasone dipropionate as a synthetic corticosteroid. It is indicated for the topical treatment of plaque psoriasis.
Details :
WYNZORA is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis. It is based on PAD™ Technology, which enables stability of both calcipotriene and betamethasone dipropionate in a...
Details :
Akvano (Calcipotriol) is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Psoriasis.
Details :
Positive results from the Phase III study with Lipidor’s drug candidate AKP02, which is based on calcipotriol alone & in combination with betamethasone, show that AKVANO® technology works well for drugs for treatment of psoriasis.
Details :
Calcipotriol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Psoriasis.
Reset All
